翻译：目前结直肠癌肝转移colorectal liver metastases CRLM患者总体5年生存率仍不足20。以手术为主的局部治疗能够使CRLM患者获得NED获得NED后仍有超60的患者出现复发。即使获得NED之后补足围手术期6个月的辅助治疗患者复发率仍然高居不下。NED后如能接受进一步的抗肿瘤维持治疗有望降低这类患者的肿瘤复发率延长这部分患者的复发转移时间。呋喹替尼作为小分子高选择性抗血

Translation: Currently, the overall 5-year survival rate for patients with colorectal liver metastases (CRLM) is still less than 20%. Surgery-based local treatment can achieve no evidence of disease (NED) in CRLM patients, but over 60% of patients experience recurrence even after achieving NED. Even with adjuvant therapy for 6 months after achieving NED, the recurrence rate remains high. If further anti-tumor maintenance treatment can be administered after achieving NED, it may reduce the tumor recurrence rate and prolong the time to recurrence and metastasis for these patients. Fruquintinib, as a small molecule highly selective anti-angiogenesis inhibitor, has clear anti-tumor efficacy and manageable adverse reactions. The Chinese Society of Clinical Oncology (CSCO) guidelines have included fruquintinib as a recommended first-line therapy for colorectal cancer (CRC). The clinical efficacy and safety of fruquintinib as maintenance treatment after completing adjuvant chemotherapy for advanced CRC with NED deserve further exploration. The aim of this study is to investigate the clinical efficacy and safety of fruquintinib as maintenance treatment for advanced CRC after completing adjuvant chemotherapy and achieving NED.